Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Effectiveness and Safety of Three Protocols Usin Li-ESWT for Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03308409
Recruitment Status : Recruiting
First Posted : October 12, 2017
Last Update Posted : December 20, 2019
Sponsor:
Information provided by (Responsible Party):
Boston Medical Group

Tracking Information
First Submitted Date  ICMJE October 9, 2017
First Posted Date  ICMJE October 12, 2017
Last Update Posted Date December 20, 2019
Actual Study Start Date  ICMJE August 1, 2017
Estimated Primary Completion Date July 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 9, 2017)
IIEF-EF score 6 months after completing the treatment [ Time Frame: 6 month follow-ups ]
This is a highly sensitive and specific scale for detecting changes in erectile function in response to treatment. The degree of dysfunction is scored on a range of 0 to 30 points on the Erectile Functioning domain (questions 1, 2, 3, 4, 5, 15). The categories are: severe between 0 and 10, moderate between 11 and 16, mild-to-moderate between 17 and 21, mild between 22 and 25, and no ED between 26 and 30.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 9, 2017)
  • Erection Hardness Score [ Time Frame: 3-month and 6-month follow-ups ]
    The EHS has a single Likert scale: 0 = Penis does not increase in size; 1= the penis increases in size but is not hard; 2 = the penis is hard but not hard enough for penetration; 3 = the penis is hard enough for penetration but not completely hard; 4 = the penis is completely hard and fully rigid
  • Clinical improvement [ Time Frame: 6-month follow-ups ]
    For patients with moderate ED, a 5-point increase in the IIEF-EF score is considered improvement. For patients with mild ED a 2-point increase on this scale is considered improvement. And for those with severe ED a 7-point change is considered improvement.
  • Number of satisfactory relations [ Time Frame: 3-month and 6-month follow-ups ]
    According to the patient's journal records. For the purpose of this study, satisfactory relations are defined as the increase in rigidity and duration of the erection as evaluated by the patient and his partner. For patients who were not able to penetrate before treatment, satisfactory relations will include not only an increase in rigidity and duration of the erection but also the ability to penetrate.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Comparative Effectiveness and Safety of Three Protocols Usin Li-ESWT for Erectile Dysfunction
Official Title  ICMJE Clinical Randomized Multicentric Trial to Evaluate the Comparative Effectiveness and Safety of Three Protocols Using Low-intensity Shock Waves for the Treatment of Erectile Dysfunction
Brief Summary The patients with primary erectile dysfunction (IIEF-EF <26 points), will be randomly assigned to three shockwave treatment protocols: Protocol 1 six sessions, one per week; Protocol 2, six initial sessions, one per week, followed by monthly maintenance sessions (every 4 weeks) for five months; Protocol 3, six monthly sessions. The EHS and IIEF-EF scores will be compared as well as the possible adverse events from the therapy upon beginning and completing the treatment and at the 3-month and 6-month follow-ups. Self-esteem and quality of life will also be evaluated using the SEAR scale.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Treatment
Condition  ICMJE Erectile Dysfunction
Intervention  ICMJE Other: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
Study Arms  ICMJE
  • Active Comparator: Protocol 1
    Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
    Intervention: Other: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
  • Experimental: Protocol 2
    Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
    Intervention: Other: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
  • Experimental: Protocol 3
    Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
    Intervention: Other: Low-intensity extracorporeal shock wave therapy (Li-ESWT)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 9, 2017)
279
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 2021
Estimated Primary Completion Date July 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Men over 18 years of age
  • Presence of ED for more than 3 months in over 50% of sexual intercourses.
  • Baseline ED domain score under 26 on the IIEF-15 EF domain.
  • Patient agrees to participate in the trial by providing signed informed consent.

Exclusion Criteria:

  • EHS score of 4.
  • Patients with an INR over 3.
  • Patients with sickle-cell anemia.
  • Patients with clinical suspicion of hypogonadism (AMS over 36).
  • Endocrine diseases that present with ED, such as acromegaly, gigantism, Addison's disease, hyperprolactinemia, androgen deficiency.
  • Active vesicular, prostrate or colon cancer.
  • Radical prostatectomy or other radical pelvic surgery.
  • History of pelvic radiation therapy.
  • Patients with ED of psychological origin.
  • Spinal cord injury or other neurological diseases associated with ED.
  • Anatomical penile dysfunction, penile implant.
  • Patients with active infections or lesions on the penis or pubic area.
  • Patients with ED secondary to drug therapy (antiandrogen therapy, alpha blockers for BPH, use of corticosteroids, medication for Parkinson's disease, antipsychotics).
  • Abuse of psychoactive substances.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: José Saffon, Doctor 3208899777 ext 104 jpsaffon@bostonmedical.com.co
Listed Location Countries  ICMJE Colombia,   Mexico
Removed Location Countries Brazil
 
Administrative Information
NCT Number  ICMJE NCT03308409
Other Study ID Numbers  ICMJE BMGC-3
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Boston Medical Group
Study Sponsor  ICMJE Boston Medical Group
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Boston Medical Group
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP